Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

AceLink Starts China Phase II Trial of Novel GCS Inhibitor for Fabry Disease

publication date: Aug 10, 2023

AceLink Therapeutics started a China Phase II trial of its lead drug, a proposed treatment for males with previously untreated Fabry disease. AL01211 is a novel oral, non-brain penetrant glucosylceramide synthase (GCS) inhibitor. The GCS inhibitor catalyzes the first step in the synthesis of glycosphingolipids to reduce the synthesis of glycosphingolipids, the cause of Fabry and Gaucher diseases. AceLink positions AL01211 as an alternative to frequent IV infusions of enzyme replacement therapy. AceLink, which is supported by China venture capital companies, is located in the San Francisco Bay area. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital